Study shows nitrous oxide is an effective treatment for major depression

Nov. 30 (UPI) -- A recent study indicates that patients suffering from major depressive disorder who have not responded to conventional antidepressants might experience relief through short-term nitrous oxide treatment, researchers revealed Sunday.

The research, carried out by the University of Birmingham and published in eBioMedicine, "evaluated the best available clinical data to demonstrate how medically administered nitrous oxide (NO) can provide rapid improvement in depressive symptoms for adults with major depressive disorder (MDD) and treatment-resistant depression (TRD)," according to a press release.

In three clinical trials, a single session of inhaled nitrous oxide at a 50% concentration led to a swift and noticeable reduction in depressive symptoms within 24 hours. However, the effect did not last beyond one week. Repeated sessions over multiple weeks were associated with more enduring benefits, suggesting that ongoing treatments may be necessary for long-term symptom relief, the researchers noted.

Nitrous oxide is believed to act on the brain's glutamate receptors similarly to ketamine, a fast-acting antidepressant that temporarily alters brain chemistry and is used clinically to treat depression.

The study also highlighted that a limited number of existing trials created inconsistencies in how depressive symptoms were measured and reported. Researchers emphasized the importance of further studies and additional clinical trials to validate the findings.

Plans are underway for the first trial within Englands National Health Service to evaluate whether nitrous oxide can serve as a viable long-term treatment option for major depressive disorder. "These results will help determine how nitrous oxide might be incorporated into NHS care and could broaden the range of innovative treatments available for patients unresponsive to conventional therapies," the release stated.

The team additionally examined potential side effects, noting that higher concentrations above 50% increased the likelihood of adverse reactions.

Author's Comment: Potential of Nitrous Oxide in Treating Depression

The recent findings from the University of Birmingham's study shed light on a promising avenue for patients struggling with major depressive disorder (MDD) and treatment-resistant depression (TRD). The use of nitrous oxide, commonly known as laughing gas, offers a rapid reduction in depressive symptoms for some patients, especially those who have not responded to traditional antidepressants.

The clinical trials outlined in the research point to a significant reduction in symptoms within just 24 hours after a single session of nitrous oxide inhalation at a 50% concentration. While the effects were temporary, the data suggest that repeated treatments could offer longer-lasting relief. This is particularly noteworthy, as conventional antidepressants often require weeks to show results, and many patients find them ineffective. The comparison to ketamine, another fast-acting antidepressant, adds to the intrigue of nitrous oxide as a potential treatment for depression.

However, it's important to recognize the limitations of the study. The researchers themselves noted inconsistencies in how depressive symptoms were measured across trials, underscoring the need for more extensive research to validate these findings. The current study offers a promising preliminary look, but more robust clinical trials will be necessary to establish nitrous oxide as a reliable treatment option for MDD and TRD.

With plans for a National Health Service trial underway, it will be crucial to evaluate the long-term efficacy and safety of nitrous oxide, particularly given the potential side effects at higher concentrations. If further research supports these early findings, nitrous oxide could become an innovative tool in treating patients who have exhausted other options.

Sources:

• Report: Nitrous oxide found effective as major depression treatment